Central Pontine Myelinolysis (CPM) is a neurological disorder that involves the destruction of the myelin sheath in the central part of the brainstem, particularly in the pons. This condition is often associated with rapid and severe changes in serum sodium levels, such as those that can occur during rapid correction of hyponatremia
AstraZeneca Funding research into the use of glial cell line-derived neurotrophic factor (GDNF) for neuroprotection in various conditions, including CPM.
Biogen Exploring the potential of its BACE inhibitors, which target beta-amyloid plaques in Alzheimer's disease, for neuroprotection in other neurological disorders, potentially including CPM.
Roche Supporting research on the role of aquaporins (water channels) in myelin damage, which could lead to new therapeutic targets for CPM and other myelinolytic disorders.
Siemens Healthineers Developing advanced MRI technology with improved resolution and precision, potentially aiding in earlier and more accurate diagnosis of CPM.
Medtronic Investing in research on brain stimulation therapies for various neurological conditions, which could potentially be explored for applications in CPM management.
Integra LifeSciences Offering specialized catheters and other medical devices used in supportive care and management of neurological patients, including those with CPM.
List of Central Pontine Myelinolysis Key Companies in the Market
Central Pontine Myelinolysis Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)